mohamed mudarres

mohamed mudarres

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2024 in Cureus
Verified
Journal Article
Open access
PDF file
MMmohamed mudarres
mohamed mudarres
In this case report, the potential of pseudoephedrine to induce seizures as a side effect in elderly patients is discussed. Pseudoephedrine is commonly used to relieve nasal congestion caused by allergies, colds, or sinusitis. Still, it has been linked to several side effects, such as cardiovascular events, nervous system toxicity, and drug interactions. The report presents the case of an 83-year-old man with a medical history of diabetes, hypertension, and dyslipidemia who experienced a generalized tonic-clonic seizure after taking an over-the-counter medication containing loratadine and pseudoephedrine. The discussion underscores the need for caution when prescribing pseudoephedrine to elderly patients, particularly those with a history of seizures or other neurological conditions, and recommends alternative treatments like nasal saline irrigation or other decongestants. The case highlights the importance of comprehensive neurological assessment and diagnostic testing in patients with seizures to identify the underlying cause and guide appropriate management. Additional research is necessary to better understand the potential risks and benefits of using pseudoephedrine in elderly patients and explore alternative options for treating nasal congestion.

31 August 2024 in Cureus
Verified
Journal Article
Open access
MMmohamed mudarres
mohamed mudarres
SKSaifatullah Khan
Saifatullah Khan
Peritoneal dialysis (PD) offers a valuable alternative to hemodialysis in the management of end-stage renal disease. While PD offers several advantages, such as improved patient autonomy and preservation of residual kidney functions. It has a wide spectrum of complications, which include mechanical ones such as catheter malfunction or migration, hernias and dialysate leak, or infectious complications, which can be limited to exit site and tunnel infections or extend interiorly to cause peritonitis. One detrimental long-term complication of PD is encapsulating peritoneal sclerosis (EPS), a rare condition characterized by formation of a fibrous cocoon around the bowel loops often initiated by chronic exposure to PD solutions. Other implicated factors include peritonitis, medications and systemic inflammatory conditions. Risk of EPS increases with the duration of PD, particularly after five years. Diagnosis of EPS is challenging and often delayed, given non-specific and wide spectrum of symptoms that may range from loss of appetite to frank signs of abdominal obstruction, which result in significant consequences that can lead to treatment failure and high mortality rate. Imaging in the form of a CT abdomen is the cornerstone in diagnosis, although many patients are diagnosed intraoperatively during exploratory laparotomy. Treatment is usually directed at eliminating provoking factors and directed therapy based on the disease phase. In this case, we are discussing a 69-year-old patient presenting with signs of abdominal obstruction and found to have a large cystic lesion compressing small bowels. Eventually, patient obstruction was relieved with draining though interventional radiology after a trial of conservative management failed. Our goal is to notify our colleagues that we have a high index of suspicion coupled with prompt imaging evaluation that can facilitate early diagnosis, offering hope for improved patient outcomes through timely management strategies.

14 May 2025 in Journal of Onco-Nephrology
Verified
Journal Article
Closed access
MMmohamed mudarres
mohamed mudarres
BGBenjamin Griffin
Benjamin Griffin
BABahjat Azrieh
Bahjat Azrieh
ARAllyson Rose
Allyson Rose
NYNada Youssef
Nada Youssef
NGNaga Sumanth Gopireddy
Naga Sumanth Gopireddy
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver cancer variant, accounting for less than 1% of primary hepatic malignancies, predominantly affecting young adults. This case report presents a 24-year-old patient with altered mental status, ultimately diagnosed with metastatic FL-HCC and secondary hyperammonemic encephalopathy, a rare but critical complication. Management involved continuous renal replacement therapy (CRRT), ammonia-scavenging agents, and targeted radiotherapy for the primary tumor. This report elucidates the clinical presentation of FL-HCC, explores the pathophysiology of hyperammonemia-induced encephalopathy, and discusses management strategies, emphasizing the therapeutic role of dialysis modalities.

26 June 2026 in Kidney International Case Reports
Verified
Journal Article
Open access
MMmohamed mudarres
mohamed mudarres
JSJennifer Strouse
Jennifer Strouse
BABahjat Azrieh
Bahjat Azrieh
IKImran Khawaja
Imran Khawaja
PRPrerna Rastogi
Prerna Rastogi
MSMelissa Swee
Melissa Swee

15 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SMShehab Fareed Mohamed
Shehab Fareed Mohamed
AMAli Mohamed
Ali Mohamed
MMmohamed mudarres
mohamed mudarres
AAAZZA ELFADIL ABBAS ABDALLA
AZZA ELFADIL ABBAS ABDALLA
AAAbdulrahman Al-Mashdali
Abdulrahman Al-Mashdali
GBGautam Borthakur
Gautam Borthakur
Background: BRAF is a core component of the RAS–MAPK signaling pathway and an established oncogenic driver in several solid tumors and selected hematologic malignancies. In myeloid neoplasms, BRAF mutations are rare, and their prevalence, molecular context, and clinical significance remain incompletely defined. Available evidence is scattered across heterogeneous reports involving acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and overlap myelodysplastic/myeloproliferative neoplasms, with variable descriptions of mutation subtypes, co-mutational profiles, cytogenetic associations, therapeutic approaches, and clinical outcomes. To address these gaps, this review synthesizes data from the published literature up to 2025, summarizing the distribution, genetic landscape, and clinical impact of molecularly confirmed BRAF mutations across the spectrum of myeloid neoplasms. Results: Across published cohorts, BRAF mutations occurred in less than 1% of unselected myeloid neoplasms, with enrichment in chronic myelomonocytic leukemia and therapy-related or secondary acute myeloid leukemia. Both V600E and non-V600E variants were observed, typically within a complex genomic background involving ASXL1, TET2, DNMT3A, SRSF2, and RAS-pathway mutations. Acute myeloid leukemia cases showed poor prognosis, with median overall survival measured in months, whereas myelodysplastic syndromes and chronic myelomonocytic leukemia demonstrated relatively longer survival. Targeted MAPK inhibition produced hematologic responses in selected cases but rarely resulted in durable molecular clearance. Conclusions: BRAF mutations in myeloid neoplasms are rare, heterogeneous, and usually represent secondary events in clonal evolution. Although mutation clearance appears prognostically relevant, current targeted approaches provide limited durability, underscoring the need for prospective studies in this setting.

13 August 2026 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
EAElrazi Ali
Elrazi Ali
Marrita RabadiMarrita Rabadi
Marrita Rabadi
RARuba Adel Aweer
Ruba Adel Aweer
ESEihab Subahi
Eihab Subahi
EAElabbass Ali Abdelmahmuod
Elabbass Ali Abdelmahmuod
SMShehab Mohamed
Shehab Mohamed
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the management of type 2 diabetes mellitus (T2DM) due to their survival benefits. However, these agents are associated with increases in hemoglobin (Hgb) and hematocrit (Hct), raising concern for secondary polycythemia or erythrocytosis and potential thrombotic risk. The clinical significance of these hematologic changes remains unclear. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed, Scopus, and Embase were searched up to February 2026 for studies evaluating the effect of SGLT2 inhibitors on hematologic parameters in adults with T2DM. Patients with primary polycythemia, end-stage renal disease (ESRD), or heart failure were excluded. Primary outcomes were changes in Hgb and Hct. Secondary outcomes included the incidence of erythrocytosis/polycythemia and thrombotic events. Results: A total of 10 studies met inclusion criteria, comprising randomized and observational studies, with follow-up ranging from 8 weeks to 24 months. SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, were consistently associated with increases in Hgb and Hct. Across three randomized controlled trials, SGLT2 inhibitors significantly increased hematocrit (3 studies, 171 patients, pooled mean difference + 2.29%, 95% CI 1.48 to 3.09) and hemoglobin (3 studies, 171 patients, pooled mean difference + 0.51 g/dL, 95% CI 0.28 to 0.74) compared with placebo. Real-world data (9,646 patients) reported an increase in polycythemia prevalence from 2.4% to 9.7%, with severe cases in 1.4% of patients. Limited data suggested a potential association with thrombotic events, with one observational study of 100 patients with JAK2-unmutated erythrocytosis reporting a 10% event rate. Hematologic changes were observed early after treatment initiation and appeared reversible following drug discontinuation. Conclusions: In patients with type 2 diabetes, ESRD, or heart failure, SGLT2 inhibitor use is associated with consistent increases in hemoglobin and hematocrit. Although these effects may contribute to cardiovascular benefit, a subset of patients may develop clinically significant erythrocytosis. Clinicians should be aware of this potential effect and monitor high-risk individuals. Larger prospective studies are needed to better define the clinical significance of these findings.